ACTRN12611000461998进行中（未招募）2 期
Paediatric patients testing eculizumab for atypical hemolytic-uremic syndrome for safety and efficacy.
适应症
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 1 Months 至 18 Years（—）
- 性别
- All
入选标准
- •Signed informed consent.
- •Patients from 1 month to 18 years diagnosed with aHUS
排除标准
- •Typical hemolytic-uremic syndrome (HUS), malignancy within 5 years of screening, HUS related to infection or bone marrow transplant or vitamin B12 deficiency, systemic lupus erythematosus (SLE), meningococcal/pneumococcal disease history.
研究者
相似试验
终止
2 期
Study to evaluate if eculizumab is efficient and safe enough to be used for treatment of adults with atypical hemolytic-uremic syndromeACTRN12611000498998Alexion Pharmaceuticals Australasia Pty Ltd30
终止
2 期
A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum DisorderNeuromyelitis OpticaNeuromyelitis Optica Spectrum DisorderNCT04155424Alexion Pharmaceuticals, Inc.5
已完成
2 期
An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic SyndromeAtypical Hemolytic-Uremic SyndromeNCT01193348Alexion Pharmaceuticals, Inc.22
尚未招募
2 期
Phase II trial of nivolumab for pediatric and adult relapsing/refractory ALK+ anaplastic large cell lymphoma, for evaluation of response in patients with progressive disease (Cohort 1) or as consolidative immunotherapy in patients in complete remission after relapse (Cohort 2)10025321ALCLNL-OMON56001Gustave Roussy2
进行中（未招募）
1 期
ivolumab for pediatric and adult relapsing/refractory ALK+ anaplastic large cell lymphoma in patients with progressive disease or in patients in complete remission after relapseRelapsing/Refractory ALK+ Anaplastic Large cell LymphomaEUCTR2018-001447-31-NLGustave Roussy43